The Congressional Research Service (CRS) has issued a report titled “Compounded Drugs” to address the risks and oversight issues raised by the growing volume of drugs produced through nontraditional compounding— that is, outside the context of a pharmacist creating a prescription in consultation with a licensed health provider to treat a specific patient. Among other matters, the report examines the 2012 fungal meningitis outbreak traced to a compounding pharmacy, recent recalls, information about the compounded drugs currently produced, who is producing them, and information on adverse events. CRS prepared the report in response to policymaker questions about how best to ensure the safety of compounded drugs given the traditional state role in regulating pharmacies and the lack of any federal requirements for adverse event reporting in this sector.